US FDA’s 2019 Drugs Trials Snapshots show female participation in clinical trials of the drugs approved during the past year increased, although ethnic diversity remains an issue.
Following an inspection at its Ireland site, Almac received compliance certification for its Almac Adapt Just in Time’ clinical packaging and labelling manufacturing services.
Lack of reproducibility in drug discovery has thrown the industry into crisis, scientists from Molecule and Arctoris claim, and suggest their discovery platform answers this challenge.
Abbott’s glucose sensing technology and a tubeless insulin delivery system developed by Insulet are set to create a personalized diabetes management solution.
In its latest deal, BIA Separations brings to market an elution method developed by the University of Zagreb, which helps preserve viruses’ integrity, infectivity, and potency.
Bioavailability of water insoluble compounds, such as CBD, enhanced up to 15 times with the technology of Solmic, leading to its acquisition by Betterlife.
Antibody-focused service providers merge their offerings to create a ‘seamless workflow’ on antibody-drug conjugates to help save developers’ time and costs.
Funding from Gamma supports the development of Univercells’ biomanufacturing platform and bioreactors, with the latter looking to expand into the fast-growing gene therapy segment.
Aiming to improve flexibility in bioprocessing, Eppendorf launches SciVario twin, a bioreactor control system enabling remote monitoring of microbial and cell culture processes.
Aiming to support drug developers in issues related to market insights, engagement, and access, Synaptiq enters the market backed by three consultancy agencies.
Strict timeframes set from sponsors in clinical studies often come in conflict with patients’ convenience, forming the biggest challenge to patient-centricity, says Medidata.
The potential of a virtual approach in eliminating site management costs during clinical trials is the main motive, even for ‘conservative’, hesitant developers, says Syneos.
